Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

Market Cap	45.18B +0.3%
Revenue (ttm)	6.83B +3.5%
Net Income	887.89M +119.2%
EPS	1.04 +121.0%
Shares Out	855.14M
PE Ratio	53.43
Forward PE	44.75
Dividend	0.13 (0.23%)
Ex-Dividend Date	Jun 17, 2025

Volume	10,837,538
Average Volume	11,602,933
Open	55.60
Previous Close	55.43
Day's Range	54.70 - 56.95
52-Week Range	41.61 - 71.90
Beta	0.68
RSI	51.57
Earnings Date	Mar 30, 2026

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300347

Financial Performance

In 2025, SHE:300347's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.